The UK national breast cancer screening programme for survivors of Hodgkin lymphoma detects breast cancer at an early stage.
Authors
Howell, Sacha JSearle, C
Goode, Valerie
Gardener, T
Linton, Kim M
Cowan, Richard A
Harris, Maggie A
Hopwood, Penelope
Swindell, Ric
Norman, Alison
Kennedy, Jennifer
Howell, Anthony
Wardley, Andrew M
Radford, John A
Affiliation
Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, UK. Showell@picr.man.ac.ukIssue Date
2009-08-18
Metadata
Show full item recordAbstract
BACKGROUND: Supradiaphragmatic radiotherapy (SRT) to treat Hodgkin's lymphoma (HL) at a young age increases the risk of breast cancer (BC). A national notification risk assessment and screening programme (NRASP) for women who were treated with SRT before the age of 36 years was instituted in the United Kingdom in 2003. In this study, we report the implementation and screening results from the largest English Cancer Network. METHODS: A total of 417 eligible women were identified through cancer registry/hospital databases and from follow-up (FU) clinics. Screening results were collated retrospectively, and registry searches were used to capture BC cases. RESULTS: Of the 417 women invited for clinical review, 243 (58%) attended. Of these 417 women, 23 (5.5%) have been diagnosed with BC, a standardised incidence ratio of 2.9 compared with the age-matched general population. Of five invasive BCs diagnosed within the NRASP, none involved axillary lymph nodes compared with 7 of 13 (54%) diagnosed outside the programme (P<0.10). The mean latency for BC cases was 19.5+/-8.35 years and the mean FU duration for those unaffected by BC was 14.6+/-9.11 years (P<0.01), suggesting that those unaffected by BC remain at high risk. Recall and negative biopsy rates were acceptable (10.5 and 0.8%, respectively). CONCLUSIONS: The NRASP appears to detect BC at an early stage with acceptable biopsy rates, although numbers are small. Determination of NRASP results on a national basis is required for the accurate evaluation of screening efficacy in women previously treated with SRT.Citation
The UK national breast cancer screening programme for survivors of Hodgkin lymphoma detects breast cancer at an early stage. 2009, 101 (4):582-8 Br. J. CancerJournal
British Journal of CancerDOI
10.1038/sj.bjc.6605215PubMed ID
19672261Type
ArticleLanguage
enISSN
1532-1827ae974a485f413a2113503eed53cd6c53
10.1038/sj.bjc.6605215
Scopus Count
Related articles
- Screening mammography for young women treated with supradiaphragmatic radiation for Hodgkin's lymphoma.
- Authors: Lee L, Pintilie M, Hodgson DC, Goss PE, Crump M
- Issue date: 2008 Jan
- Breast Imaging in Women Previously Irradiated for Hodgkin Lymphoma.
- Authors: Horst KC, Fero KE, Hancock SL, Advani RH, Ikeda DM, Daniel B, Rosenberg SA, Donaldson SS, Hoppe RT
- Issue date: 2016 Apr
- Risk of breast cancer and breast cancer characteristics in women treated with supradiaphragmatic radiation for Hodgkin lymphoma: Mayo Clinic experience.
- Authors: Wahner-Roedler DL, Nelson DF, Croghan IT, Achenbach SJ, Crowson CS, Hartmann LC, O'Fallon WM
- Issue date: 2003 Jun
- Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes.
- Authors: De Bruin ML, Sparidans J, van't Veer MB, Noordijk EM, Louwman MW, Zijlstra JM, van den Berg H, Russell NS, Broeks A, Baaijens MH, Aleman BM, van Leeuwen FE
- Issue date: 2009 Sep 10
- Impact of Early Breast Cancer Screening on Mortality Among Young Survivors of Childhood Hodgkin's Lymphoma.
- Authors: Hodgson DC, Cotton C, Crystal P, Nathan PC
- Issue date: 2016 Jul
Related items
Showing items related by title, author, creator and subject.
-
Treatment for non small cell lung cancer, small cell lung cancer and pleural mesothelioma within the EORTC Lung Cancer Group: past, present and future.O'Brien, M; van Meerbeeck, J; Surmont, V; Faivre-Finn, Corinne (2012)
-
Ovarian cancer among 8,005 women from a breast cancer family history clinic: no increased risk of invasive ovarian cancer in families testing negative for BRCA1 and BRCA2.Ingham, S; Warwick, J; Buchan, I; Sahin, S; O'Hara, Catherine; Moran, Anthony; Howell, Anthony; Evans, D; Centre for Health Informatics, Institute of Population Health, The University of Manchester, Manchester, UK. (2013-06)Mutations in BRCA1/2 genes confer ovarian, alongside breast, cancer risk. We examined the risk of developing ovarian cancer in BRCA1/2-positive families and if this risk is extended to BRCA negative families.
-
AZD8186 study 1: phase I study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumour activity of AZD8186 in patients with advanced castration-resistant prostate cancer (CRPC), squamous non-small cell lung cancer, triple negative breast cancer and with PTEN-deficient/mutated or PIK3CB mutated/amplified malignancies, as monotherapy and in combination with vistusertib (AZD2014) or abiraterone acetate.Lillian, S; De Bono, J; Higano, C; Shapiro, G; Brugger, W; Mitchell, P; Colebrook, S; Klinowska, T; Barry, S; Dean, Emma J; et al. (2016-12)